表紙
市場調查報告書

過食性障礙 (BED):機會分析與預測 2027年

Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027

出版商 GlobalData 商品編碼 696457
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
過食性障礙 (BED):機會分析與預測 2027年 Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027
出版日期: 2018年06月11日內容資訊: 英文 107 Pages
簡介

本報告提供全球過食性障礙 (BED) 市場相關資料,流行病學,病因,病理學,症狀,包含診斷,及目前管理策略,BED市場收益,目前治療選項,未滿足需求,機會,及影響主要7個國家的治療藥銷售額的市場成長的影響要素分析,開發平台分析,競爭情形分析等調查。

第1章 目錄

第2章 過食性障礙 (BED):摘要整理

  • BED市場預計急速成長
  • 以併發症做為目標的是可信賴的BED治療藥開發途徑
  • 認識不足是BED治療的最大未滿足需求
  • Dasotraline 預計成為BED的主要藥物療法
  • 醫生的見解

第3章 簡介

第4章 疾病概要

  • 病因、病理學
  • 分類或分期系統

第5章 流行病學

  • 疾病的背景
  • 風險因素、合併症
  • 全球、過去趨勢
  • 預測手法
  • BED的流行病學預測
  • 討論

第6章 目前治療選項

  • 概要
  • 心理治療

第7章 未滿足需求、機會的評估

  • 概要
  • BED的認識改善、診斷
  • 已經核准BED藥物療法的大池
  • 長期性藥物療法的效果臨床證據
  • 進行心理治療的增加

第8章 R&D策略

  • 概要
  • 臨床實驗設計

第9章 開發平台分析

  • 概要
  • 非標籤藥物BED產品臨床開發

第10章 開發平台評估分析

  • 主要的開發平台藥物臨床基準
  • 主要的開發平台藥物的商業基準
  • 競爭評估
  • 銷售額的十年預測

第11章 附錄

目錄
Product Code: GDHC086POA

Binge Eating Disorder (BED) is associated with a large number of comorbidities including obesity, depression, anxiety, and behavioral disorders such as ADHD and Obsessive Compulsive Disorder (OCD). Key opinion leaders indicated that the selection of pharmacotherapy to treat Binge Eating Disorder (BED) is dependent on each patient's complex combinations of symptoms. The majority of clinical development in Binge Eating Disorder (BED) has focused on drugs that have a primary indication for one of these comorbidities.

Binge Eating Disorder (BED) was first noted by Albert Stunkard in 1959, who descriBinge Eating Disorder (BED) the consuming of large quantities of food at irregular intervals and its link to obesity. However, Binge Eating Disorder (BED) was only officially recognized as a distinct eating disorder in 2013, with the publication of the Diagnosis and Statistical Manual, Fifth Edition. Since its recognition as a distinct clinical disorder, awareness of Binge Eating Disorder (BED) has been slowly increasing, but Binge Eating Disorder (BED) is currently only properly diagnosed in a small proportion of cases.The lack of awareness amongst physicians and the public is the major reason that the diagnosis rate of Binge Eating Disorder (BED) is very low, at 3.2%.

Binge Eating Disorder (BED) is currently the most common eating disorder in the US. It tends to appear during late adolescence or adulthood, which is later than anorexia nervosa (AN) and bulimia nervosa (BN) typically present. Cognitive behavioural therapy (CBT) is regarded as the first-line treatment for Binge Eating Disorder (BED), but pharmacotherapy is also available as an adjunctive or alternative treatment to CBT.

Binge Eating Disorder (BED) is associated with a number of comorbidities, including depression, anxiety, and substance abuse, which must be taken into account when selecting pharmacotherapy. Similarly to other eating disorders, individuals with Binge Eating Disorder (BED) can take decades to recover without treatment, and of those who do receive treatment, some may recover in less than a year, but it more commonly takes 3-7 years. At present only one pharmacotherapy is approved in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)for the treatment of Binge Eating Disorder (BED). However, other therapeutics including antidepressants, anticonvulsants, and obesity drugs, are commonly used as off-label treatments.

The Binge Eating Disorder (BED) market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). The report "Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027", analyzes the current Binge Eating Disorder (BED) pharmacotherapy landscape and provides detailed insights into the market dynamics of this newly recognized disorder. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for Binge Eating Disorder (BED), and their sales projections within Binge Eating Disorder (BED) over the 2017-2027 forecast period.

Scope:

  • Overview of BED, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline BED market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting BED therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development and detailed analysis of pipeline products.
  • Analysis of the current and future market competition in the global BED therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global BED therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BED therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 5

2 Binge Eating Disorder (BED): Executive Summary 6

  • 2.1 Rapid Growth Expected in the BED Marketplace from 2017-2027 7
  • 2.2 Targeting Comorbidities Is a Dependable BED Treatment Development Route 8
  • 2.3 Lack of Awareness Is the Greatest Unmet Need in BED Care 9
  • 2.4 Dasotraline Expected to Become a Leading Pharmacotherapy for BED by 2027 10
  • 2.5 What Do Physicians Think? 11

3 Introduction 14

  • 3.1 Catalyst 14
  • 3.2 Related Reports 15

4 Disease Overview 16

  • 4.1 Etiology and Pathophysiology 16
    • 4.1.1 Etiology 16
    • 4.1.2 Pathophysiology 17
  • 4.2 Classification or Staging Systems 20

5 Epidemiology 21

  • 5.1 Disease Background 21
  • 5.2 Risk Factors and Comorbidities 22
  • 5.3 Global and Historical Trends 22
  • 5.4 Forecast Methodology 24
    • 5.4.1 Sources 25
    • 5.4.2 Forecast Assumptions and Methods 28
  • 5.5 Epidemiological Forecast for BED (2017-2027) 33
    • 5.5.1 12-Month Diagnosed Prevalent Cases of BED 33
    • 5.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of BED 34
    • 5.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of BED 35
    • 5.5.4 12-Month Diagnosed Prevalent Cases of BED by BMI 36
    • 5.5.5 12-Month Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder 37
    • 5.5.6 12-Month Diagnosed Prevalent Cases of BED with Substance Abuse Disorder 38
  • 5.6 Discussion 39
    • 5.6.1 Epidemiological Forecast Insight 39
    • 5.6.2 Limitations of Analysis 40
    • 5.6.3 Strengths of Analysis 41

6 Current Treatment Options 42

  • 6.1 Overview 42
  • 6.2 Psychotherapy 45

7 Unmet Needs and Opportunity Assessment 48

  • 7.1 Overview 48
  • 7.2 Improved Awareness and Diagnosis of BED 49
  • 7.3 Larger Pool of Approved BED Pharmacotherapies 51
  • 7.4 Clinical Evidence for Long-Term Pharmacotherapy Efficacy 52
  • 7.5 Increased Access to Psychotherapy 53

8 R&D Strategies 54

  • 8.1 Overview 54
    • 8.1.1 Targeting the Brain's Reward System Receptors 55
    • 8.1.2 Targeting Key Comorbidities of BED 55
    • 8.1.3 Repurposing Weight-Loss Therapies 56
  • 8.2 Clinical Trial Design 57
    • 8.2.1 Binge Eating or Psychological Endpoints 58
    • 8.2.2 Psychotherapy Inclusive 60
    • 8.2.3 Clinical Trial Duration 60

9 Pipeline Assessment 62

  • 9.1 Overview 62
  • 9.2 Clinical Development of Off-Label BED Products 65

10 Pipeline Valuation Analysis 67

  • 10.1 Clinical Benchmark of Key Pipeline Drugs 67
  • 10.2 Commercial Benchmark of Key Pipeline Drugs 68
  • 10.3 Competitive Assessment 69
  • 10.4 Top-Line 10-Year Forecast 71
    • 10.4.1 US 76
    • 10.4.2 5EU 77
    • 10.4.3 Japan 79

11 Appendix 80

  • 11.1 Bibliography 80
  • 11.2 Abbreviations 86
  • 11.3 Methodology 88
    • 11.3.1 Forecasting Methodology 88
    • 11.3.2 Diagnosed Patients 88
    • 11.3.3 Percent Drug-Treated Patients 89
    • 11.3.4 Drugs Included in Each Therapeutic Class 89
    • 11.3.5 Launch and Patent Expiry Dates 90
    • 11.3.6 General Pricing Assumptions 90
    • 11.3.7 Individual Drug Assumptions 91
    • 11.3.8 Generic Erosion 98
    • 11.3.9 Pricing of Pipeline Agents 98
    • 11.3.10 Influence of Clinical Evidence on Off-Label Use in BED 99
  • 11.4 Primary Research - KOLs Interviewed for This Report 100
  • 11.5 Primary Research - Prescriber Survey 102
  • 11.6 About the Authors 103
    • 11.6.1 Analysts 103
    • 11.6.2 Therapy Area Directors 103
    • 11.6.3 Epidemiologist 104
    • 11.6.4 Managing Epidemiologist 104
    • 11.6.5 Global Director of Therapy Analysis and Epidemiology 105
    • 11.6.6 Global Head and EVP of Healthcare Operations and Strategy 105
  • 11.7 About GlobalData 106
  • 11.8 Contact Us 106
  • 11.9 Disclaimer 107

List of Tables

  • Table 1: BED: Key Metrics in the 7MM 6
  • Table 2: BED Severity Grading as Defined by DSM-5 20
  • Table 3: Risk Factors and Comorbidities for BED 22
  • Table 4: Treatment Guidelines for BED 44
  • Table 5: Leading Treatments for BED, 2017 45
  • Table 6: Comparison of Therapeutic Classes in Development for BED, 2017-2027 65
  • Table 7: Approved Drugs in Development for BED, 2018 65
  • Table 8: Clinical Benchmark of Key Pipeline Drugs - BED 68
  • Table 9: Commercial Benchmark of Key Pipeline Drugs - BED 69
  • Table 10: Key Events Impacting Sales for BED, 2017-2027 75
  • Table 11: Global Drivers and Barriers in the BED Market, 2017-2027 75
  • Table 12: Key Historical and Projected Launch Dates (BED Approval Date in Parentheses) 90
  • Table 13: Key Historical and Projected Patent Expiry Dates for BED 90
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 102

List of Figures

  • Figure 1: Global Sales Forecast by Country for BED in 2017 and 2027 8
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Vyvanse 11
  • Figure 3: Anatomy of the Reward System in the Human Brain 18
  • Figure 4: Age-Standardized 12-Month Diagnosed Prevalence of BED in the 7MM, Ages ≥13 Years, 2017 24
  • Figure 5: Sources Used and Not Used for Diagnosed Prevalent Cases of BED 25
  • Figure 6: Sources Used and Not Used for Diagnosed Prevalent Cases of BED by BMI 26
  • Figure 7: Sources Used for Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder 27
  • Figure 8: Sources Used for Diagnosed Prevalent Cases of BED with Substance Abuse Disorder 28
  • Figure 9: 12-Month Diagnosed Prevalent Cases of BED, 7MM, Men and Women, Ages ≥13 Years, N, 2017 34
  • Figure 10: Age-Specific 12-Month Diagnosed Prevalent Cases of BED, 7MM, Men and Women, Ages ≥13 Years, N, 2017 35
  • Figure 11: Sex-Specific 12-Month Diagnosed Prevalent Cases of BED, 7MM, Ages ≥13 Years, N, 2017 36
  • Figure 12: 12-Month Diagnosed Prevalent Cases of BED by BMI, 7MM, Men and Women, Ages ≥13 Years, N, 2017 37
  • Figure 13: 12-Month Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder, 7MM, Men and Women, Ages ≥13 Years, N, 2017 38
  • Figure 14: 12-Month Diagnosed Prevalent Cases of BED with Substance Abuse Disorder, 7MM, Men and Women, Ages ≥13 Years, N, 2017 39
  • Figure 15: Breakdown of the Main Psychotherapy Techniques Applied to BED 47
  • Figure 16: Unmet Needs and Opportunities in BED 49
  • Figure 17: Overview of the Clinical Development in BED 63
  • Figure 18: Key Ongoing Clinical Trials for BED Therapeutics in the 7MM 64
  • Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Vyvanse 71
  • Figure 20: Global (7MM) Sales Forecast by Country for BED in 2017 and 2027 73
  • Figure 21: Global Sales Forecast by Class for BED in 2017 and 2027 74
  • Figure 22: Sales Forecast by Class for BED in the US in 2017 and 2027 77
  • Figure 23: Sales Forecast by Class for BED in the 5EU in 2017 and 2027 78
  • Figure 24: Sales Forecast by Class for BED in Japan in 2017 and 2027 79